To determine whether human T cell lymphotropic virus type 1 (HTLV-1) infection is associated with delayed neurological development, we examined 48 Peruvian children with exposure to HTLV-1 who were identified at the Instituto Materno-Perinatal. Compared with 38 HTLV-1-seronegative children, the 10 seropositive children did not have higher rates of neurodevelopmental delay. Long-term follow-up is planned.
Among children, neurological manifestations of HIV infection include progressive encephalopathy with cognitive deficits, acquired microcephaly, myelopathy, peripheral neuropathy, language impairment, and nonprogressive developmental delay. These manifestations have been reported among children as young as 3 months of age [5] . HIV-infected children can also display delayed acquisition of motor, cognitive, and language skills, as well as progressive loss of cognitive skills [6] . High HIV-1 load was correlated with the delayed development of cognitive and motor skills, as well as with the stunting of growth [7] . Given the multiple neurologic and neurodevelopmental manifestations of HIV infection among children, the high prevalence of HTLV-1 infection among pregnant women in Lima, Peru, and the lack of information regarding the neurologic manifestations of HTLV-1 infection among children, we performed a pilot study to compare the prevalence of neurodevelopmental delay and neurologic dysfunction between a group of HTLV-1-infected children and a group of non-HTLV-1-infected children, all of whom had been breast-fed by HTLV-1-seropositive mothers.
Methods. The Instituto Materno-Perinatal (IMP) provides obstetric care to patients of low socioeconomic status living in or around Lima. Eighty-seven HTLV-1-seropositive mothers who gave birth at the IMP between 1996 and 2000 were invited to return to the IMP, where a trained social worker provided counseling regarding HTLV-1 infection and invited them to participate in the present study. Seventy-four of the 87 motherchild pairs were enrolled; each mother provided written, informed consent for her own participation, and one or both parents provided consent for each child. Human subjects committees at the IMP and at the University of Washington (Seattle) reviewed and approved the study.
A neurologist (S.M.M. or I.Q.) administered a questionnaire to each HTLV-1-seropositive mother enrolled in the study. The questionnaire concentrated on possible clinical manifestations of HTLV-1 infection, as well as on other diseases that could confound the associations being sought. All mothers were asked whether their children had constitutional symptoms or autoimmune manifestations, stiffness, spasms, lower limb weakness, or, among older children, bladder or bowel dysfunction. In addition, the questionnaire included questions about the demographics and medical histories of the mother-child pairs, the mothers' pregnancy and her breastfeeding practices, and the developmental history of each child. Pregnancy was recorded as abnormal if gestational diabetes had been present or if the mother had been exposed to x-rays or potentially toxic med- ications during the first trimester. Delivery was recorded as abnormal if forceps or vacuum delivery had been used or if premature rupture of membranes, preeclampsia, or meconium staining had occurred. All study personnel were blinded to the HTLV-1 serostatus of the children. A pediatric neurologist (L.R.) performed, for each child, a standardized neurologic examination that consisted of a detailed assessment of cranial nerve function, muscle strength and reflexes, sensation, coordination, and gait. Neurodevelopmental skills were assessed using the Denver Developmental Scale and were categorized into the following skill categories: gross motor, fine motor, language, and personalsocial skills [10] . Each skill category was measured and was compared with reference standards at which 25%, 50%, 75%, or 90% of children of that age should have attained the skill; failure to attain a skill that was attainted by 90% of children was considered abnormal. The height, weight, and head circumference of each child were recorded, and a height-for-age index was calculated to determine whether chronic malnutrition was present [8] . Malnutrition was dichotomized as present or absent. Head circumference was recorded as normal or abnormal [9] . Serum samples were tested by ELISA for HTLV-1 antibody (Platelia HTLV-1; Sanofi Pasteur). Positive results of ELISA were confirmed using a Western blot assay (HTLV-1 Blot 2.4; Genelabs Diagnostics). An individual was considered to be HTLV-1 seropositive if the result of ELISA was positive and if confirmatory Western blot assays revealed bands representing the presence of gag proteins (p24 or p19) and 2 env proteins (GD21 and rgp 46-I). If gag and env proteins were absent but other HTLV-1-specific bands were present, the results for the individual were considered to be indeterminate.
We used the x 2 test or Fisher's exact test to evaluate differences in proportions. The mean ages of HTLV-1-positive children and of HTLV-1-negative children were compared using the Mann-Whitney U test. Logistic regression was used to evaluate associations between HTLV-1 serostatus and neurodevelopmental skills; the model was adjusted for chronic malnutrition. This analysis yielded ORs and 95% CIs. All of the reported P values represent 2-sided tests. Statistical analyses were performed using SPSS for Windows, version 10.0 (SPSS).
Results. Of the 87 mother-child pairs eligible for the study, 74 mother-child pairs participated. Of the 74 children enrolled, 7 did not wish to provide a blood sample; of the 67 children for whom blood was available for testing, 44 (66%) were HTLV-1 seronegative, 12 (18%) were seropositive, and 11 (16%) had indeterminate test results. Six of the seronegative children and 2 of the seropositive children did not complete all parts of the study. The analysis included data for the 10 HTLV-1-seropositive and 38 HTLV-1-seronegative children who completed all parts of the study.
The mean age of the 48 children was 44.5 months (range, 15-71 months; SD, ‫4.11ע‬ months). The mean age of the HTLV-1-seropositive children was 49.5 months, which was not significantly older than the mean age of 43.2 months for seronegative children ( ). All children had been breast-P p .09 fed, and 7 (14%) had chronic malnutrition. Among seropositive children, the mean duration of breastfeeding was 21.3 months, which was not significantly longer than the mean duration of 20.3 months among seronegative children ( ). No sig-P p .99 nificant differences between groups were noted with regard to sex, head circumference, complications during the mother's pregnancy, complications during delivery, or chronic malnutrition (table 1) . Because HTLV-1 seroconversion in children can occur as late as 27 months of age, we repeated the analysis and excluded children !25 months of age; this analysis also revealed no statistically significant differences between groups (data not shown).
None of the 10 HTLV-1-seropositive children had evidence of neurologic dysfunction revealed by their medical history or at physical examination. By univariate analysis, no significant differences in neurodevelopmental delay were detected between the seropositive and seronegative children. After we adjusted for chronic malnutrition, we detected no significant differences in neurodevelopmental skills between the seropositive and seronegative children (table 2) . Discussion. The present pilot study was undertaken to assess the frequency of gross neurological abnormalities and of more-subtle developmental delay among HTLV-1-infected children. Our data suggest that HTLV-1 infection, unlike HIV infection, may not affect cognitive development in children. Delayed acquisition of neurodevelopmental skills was not associated with HTLV-1 infection. The high prevalence of certain abnormalities (e.g., in language, gross motor and fine motor, and social skills) among both groups raises questions about the suitability of the assessments performed in the setting of Latin America; instruments used for the assessment of developmental skills in Latin American children have not been validated.
One of the major limitations of this pilot study is the small number of subjects enrolled. In addition, neurodevelopmental assessments were performed for children of varying ages, thereby reducing our power to detect a significant association between HTLV-1 infection and neurodevelopmental delay. Also, exclusion of subjects who declined phlebotomy or did not complete all parts of the study may have biased the results. Because of these limitations, we cannot exclude the possibility of an important difference in neurodevelopment between HTLV-1-infected and non-HTLV-1-infected children.
Symptomatic neurologic infection (myelopathy/tropical spastic paraparesis) develops more frequently among HTLV-1-infected women than among HTLV-1-infected men. The majority of HTLV-1-seropositive children enrolled in the present study were male, which, perhaps, decreased our ability to detect a significant association between HTLV-1 infection and developmental delay. Other factors potentially associated with neurodevelopmental delay but not evaluated during this study include birth weight, gestational age, and HTLV-1 load. In future studies, the inclusion of PCR assay of PBMCs could be used to determine the HTLV-1 status of children with indeterminate results of serotesting and would permit examination of the association between the HTLV-1 load and the risk of neurodevelopmental delay. Future, larger-scale studies that enroll a larger number of children and incorporate additional neurodevelopmental assessments, more-detailed birth histories, and PCR assays could decrease the potential sources of bias present in our pilot study and increase the power to detect a statistically significant association between HTLV-1 infection and neurodevelopmental delay. In addition, the comparison of quantitative viral load among children who have neurodevelopmental delay and among their mothers may provide additional insight into the pathophysiology of HTLV-1 infection and the nervous system.
